Trimetazidine improves right ventricular function by increasing miR-21 expression

International Journal of Molecular Medicine

Volumn 30, Issue 4, 2012, Pages 849-855

  Liu, Fang ^a   Yin, Li ^a   Zhang, Lulu ^a   Liu, Wenhua ^a   Liu, Jingjin ^a   Wang, Yongshun ^a   Yu, Bo ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; miRNA 21; Right ventricular failure; Trimetazidine

Indexed keywords

CASPASE 3; MICRORNA 21; SEMAXANIB; TRIMETAZIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME ASSAY; HEART MUSCLE CELL; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FUNCTION; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MALE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CELLS, CULTURED; HEART FAILURE; HEART VENTRICLES; MICRORNAS; RATS; RATS, SPRAGUE-DAWLEY; TRIMETAZIDINE; UP-REGULATION; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR FUNCTION, RIGHT;

EID: 84866481796     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1078     Document Type: Article

References (33)

1. Verzi MP, McCulley DJ, De Val S, et al: The right ventricle, outflow tract, and ventricular septum comprise a restricted expression domain within the secondary/anterior heart field. Dev Biol 287: 134-145, 2005. (Pubitemid 41587484)
2. Zaffran S, Kelly RG, Meilhac SM, et al: Right ventricular myocardium derives from the anterior heart field. Circ Res 95: 261-268, 2004. (Pubitemid 39056286)
3. Haddad F, Hunt SA, Rosenthal DN and Murphy DJ: Right ventricular function in cardiovascular disease, part I: Anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation 117: 1436-1448, 2008. (Pubitemid 351501496)
4. Haddad F, Doyle R, Murphy DJ and Hunt SA: Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation 117: 1717-1731, 2008. (Pubitemid 351482595)
5. Strniskova M, Ravingerova T, Neckar J, et al: Changes in the expression and/or activation of regulatory proteins in rat hearts adapted to chronic hypoxia. Gen Physiol Biophys 25: 25-41, 2006. (Pubitemid 43797128)
6. Wang GY, McCloskey DT, Turcato S, et al: Contrasting inotropic responses to alpha1-adrenergic receptor stimulation in left versus right ventricular myocardium. Am J Physiol Heart Circ Physiol 291: H2013-H2017, 2006. (Pubitemid 44497712)
7. Manchanda SC and Krishnaswami S: Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart 78: 353-357, 1997 (Pubitemid 27479636)
8. Szwed H, Sadowski Z, Elikowski W, et al: Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). Trimetazidine in POLand. Eur Heart J 22: 2267-2274, 2001. (Pubitemid 34000982)
9. Kober G, Buck T, Sievert H and Vallbracht C: Myocardial protection during percutaneous transluminal coronary angioplasty: effects of trimetazidine. Eur Heart J 13: 1109-1115, 1992.
10. Liu X, Gai Y, Liu F, et al: Trimetazidine inhibits pressure overload-induced cardiac fibrosis through NADPH oxidase-ROS-CTGF pathway. Cardiovasc Res 88: 150-158, 2010.
11. Weiss JN, Korge P, Honda HM and Ping P: Role of the mitochondrial permeability transition in myocardial disease. Circ Res 93: 292-301, 2003. (Pubitemid 37048241)
12. Halestrap AP, Clarke SJ and Javadov SA: Mitochondrial permeability transition pore opening during myocardial reperfusion - a target for cardioprotection. Cardiovasc Res 61: 372-385, 2004. (Pubitemid 38210145)
13. Lim LP, Lau NC, Garrett-Engele P, et al: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433: 769-773, 2005. (Pubitemid 40292988)
14. Small EM, Frost RJ and Olson EN: MicroRNAs add a new dimension to cardiovascular disease. Circulation 121: 1022-1032, 2010.
15. Cheng Y and Zhang C: MicroRNA-21 in cardiovascular disease. J Cardiovasc Transl Res 3: 251-255, 2010.
16. da Costa Martins PA and De Windt LJ: MiR-21: A miRaculous Socratic paradox. Cardiovasc Res 87: 397-400, 2010.
17. Ozpolat B, Akar U, Steiner M, et al: Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells. Mol Cancer Res 5: 95-108, 2007.
18. Allgayer H: Pdcd4, a colon cancer prognostic that is regulated by a microRNA. Crit Rev Oncol Hematol 73: 185-191, 2010.
19. Bogaard HJ, Natarajan R, Henderson SC, et al: Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 120: 1951-1960, 2009.
20. Kajstura J, Cigola E, Malhotra A, et al: Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol 29: 859-870, 1997. (Pubitemid 27196513)
21. Cacciapuoti F: Echocardiographic evaluation of right heart function and pulmonary vascular bed. Int J Cardiovasc Imaging 25: 689-697, 2009.
22. Vitale C, Wajngaten M, Sposato B, et al: Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 25: 1814-1821, 2004. (Pubitemid 39330232)
23. Di Napoli P, Taccardi AA and Barsotti A: Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 91: 161-165, 2005.
24. Kantor PF, Lucien A, Kozak R and Lopaschuk GD: The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 86: 580-588, 2000. (Pubitemid 30165050)
25. Fragasso G, Palloshi A, Puccetti P, et al: A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 48: 992-998, 2006. (Pubitemid 44292461)
26. Tuunanen H, Engblom E, Naum A, et al: Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 118: 1250-1258, 2008.
27. Tatsuguchi M, Seok HY, Callis TE, et al: Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol 42: 1137-1141, 2007. (Pubitemid 46829201)
28. Sayed D, He M, Hong C, et al: MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand. J Biol Chem 285: 20281-20290, 2010.
29. Cheng Y, Liu X, Zhang S, et al: MicroRNA-21 protects against the H(2)O(2)-induced injury on cardiac myocytes via its target gene PDCD4. J Mol Cell Cardiol 47: 5-14, 2009.
30. Dong S, Cheng Y, Yang J, et al: MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J Biol Chem 284: 29514-29525, 2009.
31. Qian J, Ren X, Wang X, et al: Blockade of Hsp20 phosphorylation exacerbates cardiac ischemia/reperfusion injury by suppressed autophagy and increased cell death. Circ Res 105: 1223-1231, 2009.
32. Meyer P, Desai RV, Mujib M, et al: Right ventricular ejection fraction <20% is an independent predictor of mortality but not of hospitalization in older systolic heart failure patients. Int J Cardiol 155: 120-125, 2012.
33. Voelkel NF, Quaife RA, Leinwand LA, et al: Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 114: 1883-1891, 2006. (Pubitemid 44673364)